PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.01
Higher D/E at 1.1-1.25x AVXL's 0.01. Bruce Berkowitz would look for hidden assets justifying this higher leverage.
5.03
Much higher net debt at 1.25-1.5x AVXL's 3.51. Bill Ackman would demand clear deleveraging catalysts.
-2258.10
Both companies show negative coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
7.05
Current ratio 1.25-1.5x AVXL's 5.54. Mohnish Pabrai would examine if this strength creates buying power advantages.
No Data
No Data available this quarter, please select a different quarter.